Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21383661 | 0.88 | FPR2 (0.44) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL19368509 | 0.87 | LMNA (0.54) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL15960834 | 0.86 | TACR1 (0.50) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL17535986 | 0.86 | LMNA (0.67) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL1003120 | 0.85 | LMNA (0.50) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL18203100 | 0.84 | L3MBTL1 (0.63) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL1002715 | 0.84 | PKM (0.55) | LMNAKDM4E | |
| SCHEMBL21384089 | 0.84 | ALDH1A1 (0.41) | LMNAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL3485621 | 0.83 | AVPR1A (0.44) | LMNAKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL30683842 | 0.83 | TACR1 (0.48) | LMNAKMT2AHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20040186102-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186102-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | LMNA 3004/4885KMT2A 4263/4885HTT 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.